Join
Live feed
·
PRReleasevia Quantisnow
Connect Biopharma Holdings Limited logo

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
CNTB· Connect Biopharma Holdings Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CNTB (Connect Biopharma Holdings Limited) and more on Quantisnow.